CCCC vs ENTX: stock comparison and AI forecast
C4 Therapeutics, Inc. (CCCC) and Entera Bio Ltd. (ENTX) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
CCCC C4 Therapeutics, Inc.
- Price
- $3.10 +4.0% · 6M
- Market Cap
- $381M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
ENTX Entera Bio Ltd.
- Price
- $2.99 +118.2% · 6M
- Market Cap
- $518M
- P/E Ratio
- 9.1x
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- ENTX is 1.4 times larger than CCCC by market capitalization ($518M against $381M).
- Over the last six months ENTX returned +118.2% and CCCC +4.0%.
- ENTX carries 1.68 times debt per unit of equity, against 0.45 times for CCCC.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | CCCC | ENTX |
|---|---|---|
| Market Cap | $381M | $518M |
| P/E Ratio | – | 9.06x |
| P/B Ratio | 1.67x | 71.25x |
| EPS | $-0.99 | $0.33 |
| Book Value/Share | $1.85 | $0.04 |
| Revenue/Share | $0.26 | $0.00 |
| FCF/Share | $-0.65 | $-0.06 |
Profitability & Margins
| Metric | CCCC | ENTX |
|---|---|---|
| ROE | -39.9% | – |
| ROA | -27.4% | – |
| ROIC | -35.1% | -82.9% |
| Operating Margin | -315.9% | – |
| Net Margin | -282.2% | – |
| EBT Margin | -307.2% | – |
| Tax Rate | -0.1% | – |
Financial Health
| Metric | CCCC | ENTX |
|---|---|---|
| Current Ratio | 5.17x | 8.98x |
| D/E Ratio | 0.45x | 1.68x |
| Financial Leverage | 1.45x | 2.68x |
| Interest Coverage | 43.9x | – |
| Working Capital | $173M | $17M |
Cash Flow
| Metric | CCCC | ENTX |
|---|---|---|
| Operating Cash Flow | -$80M | -$11M |
| Free Cash Flow | -$80M | -$11M |
| Capital Spending | -$110K | -$70K |
| FCF/Sales | -247.1% | – |
| CapEx/Sales | 0.3% | – |
Operational Efficiency
| Metric | CCCC | ENTX |
|---|---|---|
| Asset Turnover | 0.10x | 0.00x |
| Receivables Turnover | 23.0x | – |
| Fixed Assets Turnover | 8.4x | 0.0x |
| Days Sales Outstanding | 16 days | – |
Income Statement
| Metric | CCCC | ENTX |
|---|---|---|
| Total Revenue | $32M | $0.00M |
| Operating Income | -$102M | -$14M |
| Net Income | -$91M | – |
| R&D Expense | $99M | $9M |
| SG&A Expense | – | $550K |
| Cost of Goods Sold | – | $0.00M |
Dividend & Shareholder Information
| Metric | CCCC | ENTX |
|---|---|---|
| Shares Outstanding | 123M | 173M |
| EPS Growth | – | 32.0% |
CCCC vs ENTX: stock comparison and AI forecast
Which is bigger, CCCC or ENTX?
ENTX is 1.4 times larger than CCCC by market capitalization ($518M against $381M).
Which stock performed better over the last six months, CCCC or ENTX?
Over the last six months ENTX returned +118.2% and CCCC +4.0%.
Which one does Intratio's AI model rank higher, CCCC or ENTX?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.